Abstract: The present invention relates to a method for assessing Atenolol with precision. A pharmaceutical composition comprising: a predefined amount of Atenolol or pharmaceutically acceptable salts thereof; and a combination of pharmaceutical excipients suitable for oral administration, wherein the method for tailoring the treatment of hypertension comprises of determining the levels of C-reactive protein, blood pressure, blood urea, and HbA1c in hypertensive patients; stratifying patients into distinct subgroups based on the identified biomarker levels; and customizing antihypertensive treatment plans for each subgroup, wherein treatment may include, but is not limited to, beta blockers such as Atenolol.

Abstract: The system comprises a collection unit for procuring doxorubicin, diethyl ether, alkaline water and a plurality of subject animals; a pre-processor unit for acclimatizing collected plurality of subject animals for 7 days standard laboratory condition; a classification processor unit for dividing subject animals into four groups; a treating unit for feeding subject animals with standard semi purified diet along with normal drinking water and standard semi purified diet along with Zam water p.o at libitum, or injecting with Dox i.p. on first day of protocol fed with standard semi purified diet along with normal drinking water or Dox i.p. on first day of protocol thereby treating with Zam water p.o at libitum for 28 days; a monitoring processor unit for monitoring physiological and behavioral changes of plurality of subject animals; and an analysis processor unit for estimating a set of biochemical parameters and stool sample of the plurality of subject animals.